Ç÷¿ìº´¿¬±¸È¸ 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 1ÀÏÂ÷ : 2023-04-06
±³À°ÀÏÀÚ : 2023-04-06
±³À°Àå¼Ò : ¾Ú¹ö¼´õ ¼¿ï Ç®¸¸È£ÅÚ
±³À°ÁÖÁ¦ : 2023³â µ¿¾Æ½Ã¾Æ Ç÷¿ìº´ Æ÷·³(4¿ù 6ÀÏ) - 1ÀÏÂ÷
ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç÷¿ìº´¿¬±¸È¸
´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581
À̸ÞÀÏ : hematology@kams.or.kr
±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 80,000¿ø
ºñ°í Àü°øÀÇ,°£È£»ç,±âŸ 50000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 09:15~09:35 Current status of hemophilia care in China Renchi Yang(Institute of Haematology and Blood Diseases Hospital, China)
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 09:35~09:55 Current Situation and Issues in Hemophilia in Japan Michio Sakai(Munakata Suikokai General Hospital, Japan)
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 09:55~10:15 Current Situation and Issues in Hemophilia in Korea Ki-Young Yoo(Korea Hemophilia Foundation, Korea)
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 10:15~10:35 Current Situation and Issues in Hemophilia in Taiwan Chia-Yao Chang(Taipei Medical University Hospital, Taiwan)
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 10:35~10:55 Current therapeutic landscape and future directions in the management of haemophilia in Australia Huyen Tran(Australia Haemophilia Centre Directors)
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 11:20~12:00 Advances in hemophilia A treatment after emicizumab Midori Shima(Thrombosis and Hemostasis Research Center, Japan)
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 12:10~12:50 Optimizing the benefits of personalized prophylaxis based on the real world experience Robert Klamroth(Vivantes Klinikum Friedrichshain, Germany)
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 13:00~13:20 Emicizumab for Individual Needs of Japanese People Living with Hemophilia: Impacts and Unsolved Issues Ei Kinai(Tokyo Medical University, Japan)
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 13:20~13:40 The role of low-dose prophylaxis and low-dose ITI for hemophilia children in developing countries. Runhui Wu(Beijing Children¡¯s Hospital, China)
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 13:40~14:00 Individualized Treatment Using Population Pharmacokinetics for Patients with Hemophilia in Taiwan Yeu-Chin Chen(Tri-Service General Hospital, Taiwan)
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 14:00~14:20 Current treatment pattern in hemophilia, based upon data the HIRA(health insurance review agency) and KBDR (Korean bleeding disorder registry) Jung Woo Han(Yonsei University Health System, Korea)
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 14:45~15:05 Hemophilia patients with Inhibitors in China Wei Liu(Blood Diseases Hospital (Institute of Hematology), China)
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 15:05~15:25 The frontiers of diagnosis and treatment in Japanese hemophilia patients with inhibitors based on prospective cohort study in Japan, J-HIS2 (Japan Hemophilia Inhibitor Study 2) Koji Yada(National Hospital Organization Osaka National Hospital, Japan)
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 15:25~15:45 Current status in hemophilia patients with inhibitors in Korea YoungShil Park(Kyung Hee University Hospital, Korea)
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 15:45~16:05 Efficacy, safety, and cost of emicizumab prophylaxis in hemophilia A patients with inhibitor: a nationwide observation study in Taiwan Jiaan-Der Wang(Taichung Veterans General Hospital, Taiwan)
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 16:30~16:50 Clinical hemostasis prediction through current monitoring technology in bleeding disorders Naruto Shimonishi(Nara Medical University, Japan)
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 16:50~17:10 The application of NGS for the diagnosis of hereditary platelet disorders Donglei Zhang(Zhongnan Hospital of Wuhan University, China)
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 17:10~17:30 Laboratory monitor of factor VIII: perceive in the era of emicizumab Te-Fu Weng(Chung Shan Medical University Hospital, Taiwan)
±³À°½Ã°£ 04-06 ±×·£µåº¼·ë 17:30~17:50 Application of primary data of coagulometer assays Jae Woo Song(Yonsei University Health System, Korea)